ValiRx Plc (VAL) Given “Speculative Buy” Rating at Beaufort Securities
ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reaffirmed by research analysts at Beaufort Securities in a research report issued on Wednesday.
Separately, Northland Securities reissued a “corporate” rating on shares of ValiRx Plc in a research report on Thursday, August 11th.
ValiRx Plc (LON:VAL) opened at 6.911 on Wednesday. ValiRx Plc has a 12-month low of GBX 5.75 and a 12-month high of GBX 25.24. The company’s market capitalization is GBX 3.62 million. The firm has a 50-day moving average of GBX 7.01 and a 200 day moving average of GBX 7.99.
ValiRx Plc Company Profile
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with MarketBeat.com's FREE daily email newsletter.